Labiotech.eu

News and Trends 4 Dec 2017

Dutch Bone Marrow Transplant for Blood Cancer could get rid of Donor Matching

Kiadis Pharma starts Phase III trials with ATIR101, a therapy that could make half-matched donors suitable for bone marrow transplant to treat blood cancer. From its Amsterdam headquarters, Kiadis Pharma is developing a technology that could solve one of the biggest problems of bone marrow transplantation: finding a donor match. Currently, a bone marrow transplant is […]

December 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Dec 2017

Novozymes and Danish Pump Producer Set Sail in Pursuit of Clean Water

As part of the company’s HelloScience initiative, Novozymes will combine its enzyme and microbial technology with Grundfos’ water pumps to provide clean water and better sanitation. Novozymes aims to improve industrial performance without harming our planet. Earlier this year, the company set up HelloScience, an online platform bringing together experts in a number of fields […]

December 4, 2017 - 2 minutesmins - By Alex Dale

Interview 4 Dec 2017

Meet the CEO Leading Italy’s Charge to Become a Major Biotech Player

Riccardo Palmisano is CEO of MolMed, the most important Italian biotech, which focuses on gene and cell therapies. We chatted about the company, which hopes to give the cancer therapies field a boost. You may have come across MolMed before, possibly in our recent piece on the top biotechs in Milan. The company was founded […]

December 4, 2017 - 7 minutesmins - By Alex Dale

More News! 2 Dec 2017

Kunstformen der Natur: 19th Century Biology Art in Exhibition

Kunstformen der Natur, by Ernst Haeckel, is a beautiful series of prints that have influenced scientists and artists alike. A Dutch exhibition shows them like never before. In the fashion of the 19th century, Ernst Haeckel was simultaneously a biologist, philosopher, physician, and artist. A Darwin contemporary, although Haeckel supported Lamarckist and other evolutionary theories that are […]

December 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Dec 2017

The Door Opens for Dutch Brain Surgery Device to Enter the Clinic

Polyganics has received €1.2M to complete the development of its dura sealant patch, which will be used to reduce the complications of brain surgery. Polyganics, based in the Groningen Medtech Hub, develops bioresorbable medical devices that aid tissue repair and regeneration. Today, the company has announced that it has received €1.2M from the European Fund for Regional […]

December 1, 2017 - 2 minutesmins - By Alex Dale

antibiotic antibody staphylococcus symphogen 1

More News! 30 Nov 2017

Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib

A Phase Ib trial will assess the capacity of Symphogen’s antibody to direct an antibiotic to Staphylococcus infections for their effective treatment. Symphogen focuses on the development of antibodies for the treatment of cancer, but will receive a $5M (€4.2M) milestone payment from Genentech for the use of one of its antibodies against Staphylococcus aureus infections. It […]

November 30, 2017 - 2 minutesmins - By Alex Dale

News and Trends 30 Nov 2017

Interview: Why Asian CROs are Turning to the European Biotech Market

The demand for contract research organizations (CROs) has been increasing steadily worldwide. With more and more clinical development programs being launched and a heightened demand for pharmaceutical products, companies in the biotechnology, pharmaceutical and medical technology industries are frequently deciding to outsource R&D processes to CROs. To give you an idea in numbers: In 2014, […]

November 30, 2017 - 11 minutesmins - By External Contributor

News and Trends 30 Nov 2017

Qiagen Joins French Biotech to Build the Next Generation of Microbiome Technology

Biomillenia harnesses the power of bacteria to keep the body healthy. The biotech has joined forces with Qiagen to develop microbiome-on-a-chip technology. Scientists around the world believe that the microbiome could hold the key to human health. One company in this area, Biomillenia, develops microbial strains from previously unculturable microbiomes to unlock its full potential. The company has now […]

November 30, 2017 - 3 minutesmins - By Alex Dale

Inside Labiotech 30 Nov 2017

Why is Erik Digman Wiklund, CFO of Targovax, reading Labiotech.eu?

Leaders & Readers: I had a chat with Erik Digman Wiklund about why he reads Labiotech.eu. He is the CFO of Targovax, a clinical-stage company focusing on the development of immuno-oncology therapies. This interview has just been lightly edited for grammar. Why do you read Labiotech.eu? I enjoy the easygoing and fun style of Labiotech, which […]

November 30, 2017 - 2 minutesmins - By Katherine Douglas

dystrophic epidermolysis bullosa proqr rna therapy

News and Trends 30 Nov 2017

RNA Therapy for Rare Skin Disease Gets Orphan Status

The EMA has granted orphan drug designation to ProQR’s QR-313, a possible first disease-modifying treatment for the rare disease dystrophic epidermolysis bullosa. Dystrophic epidermolysis bullosa (DEB) is a genetic disease that causes the skin to easily blister, severely affecting the quality of life of patients since a very early age. Current treatment is limited to […]

November 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 30 Nov 2017

Will Pharma Reach a Negative Return on its R&D Investments?

It isn’t news that pharma’s business model is in trouble, but a new report from Evaluate and number crunching from Endpoints show the size of the problem. Pharma depends on innovation, which is why it turns to biotech as the powerhouse of novel technologies. About 65% of recently drugs come from small life sciences companies […]

November 30, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 29 Nov 2017

What Exactly Happens in the Cells of People with Down’s Syndrome?

Researchers in Switzerland have taken a closer look at the cells of Down’s syndrome patients, with widespread changes in protein expression observed. Down’s syndrome, or trisomy 21, is the most common genetic disease, characterized by facial dysmorphism, learning disabilities, poor muscle tone and heart problems. Research carried out at the University of Geneva and ETH […]

November 29, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Dutch Bone Marrow Transplant for Blood Cancer could get rid of Donor Matching

Novozymes and Danish Pump Producer Set Sail in Pursuit of Clean Water

Meet the CEO Leading Italy’s Charge to Become a Major Biotech Player

Kunstformen der Natur: 19th Century Biology Art in Exhibition

The Door Opens for Dutch Brain Surgery Device to Enter the Clinic

Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib

Interview: Why Asian CROs are Turning to the European Biotech Market

Qiagen Joins French Biotech to Build the Next Generation of Microbiome Technology

Why is Erik Digman Wiklund, CFO of Targovax, reading Labiotech.eu?

RNA Therapy for Rare Skin Disease Gets Orphan Status

Will Pharma Reach a Negative Return on its R&D Investments?

What Exactly Happens in the Cells of People with Down’s Syndrome?

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!